All Updates

All Updates

icon
Filter
Funding
Triana Biomedicines emerges from stealth with USD 110 million Series A
AI Drug Discovery
Apr 6, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 6, 2022

Triana Biomedicines emerges from stealth with USD 110 million Series A

Funding

  • AI drug discovery startup Triana Biomedicines has emerged from stealth with USD 110 million in Series A financing led by Lightspeed Venture Partners. Other investors include Pfizer Ventures, Surveyor Capital, and Logos Capital. The company has raised USD 144.8 million since its inception in 2019. 

  • The Massachusetts-based company will use the proceeds from the round to fuel the company’s R&D and expansion efforts. 

  • Triana Biomedicines develops small molecule therapeutics to treat a variety of previously undruggable or poorly addressed diseases, with a focus on oncology. The company’s approach entails the discovery and development of molecular glues—a molecule that facilitates interaction between two non-interacting proteins—through its AI platform that can identify over 600 E3 ubiquitin ligases to address disease-specific targets.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.